New requirements for clinical trial sponsors to submit diversity action plans to the US Food and Drug Administration (FDA) are an important step to embed planning for diverse representation in clinical trial research. These must not, however, be implemented in ways that are detrimental to other countries’ health and research interests.

中文翻译：

---

首先，不造成伤害：临床试验多样性和包容性的全球视角

临床试验申办者向美国食品和药物管理局 (FDA) 提交多元化行动计划的新要求是将多元化代表性计划纳入临床试验研究的重要一步。然而，这些措施的实施方式不得损害其他国家的健康和研究利益。